Supplementary Materials



Supplementary Figure 1. Schematic diagram displaying how patients from the Discovery cohort contributed to the Late and Long-term cohorts. *Shaded boxes represent time-points where samples were taken from individuals* (A). Criteria used to dichotomise patients' outcome into "worse than expected" and "as/better than expected" groups, according to their risk of poor outcome as judged by the IMPACT score variables for the Discovery cohort (B) and Validation cohort (C). Histogram displaying the distribution of Z scores of IgG MAG MFI in all samples used to generate the reference distributions (D). Total serum IgM concentrations was above the normal range in 12/25 patients. *Hatched area = normal range* (E). Total serum IgG concentration was below the normal range in 13/25 patients. *Hatched area = normal range* (F). Median IgG Z score did not correlate with total serum IgG (G).



Supplementary Figure 2. (A) Polyantigenic IgM response is replicated both in a technical repeat (serum assayed again in a separate experiment) and in the purified immunoglobulin fraction (B) no such replication is seen with IgG (C) Graphs displaying replication of dominant responses to specific antigens both in a technical repeat (serum assayed again in a separate experiment) and in the purified immunoglobulin fraction (D) To assess the antigen-specificity of the autoantibodies, two serum samples positive for anti-MAG IgG and anti-GFAP IgM respectively were pre-incubated with the corresponding cognate antigen. 200 ul serum was incubated for two hours at room temperature in the presence of 1) excess antigen (5 mcg of MAG or GFAP as appropriate), 2) 2.5 mcg of both MAG and GFAP to assess the effect of total protein added versus specific cognate antigen, and 3) with no antigen added. The samples were then diluted to 1 in 1000 and run as standard on the protein microarray. Maximal attenuation of the positive autoantibody signal was seen when serum was pre-incubated with the cognate antigen; no difference was seen in negative autoantibody signals.

Supplementary Table 1. Custom Protein Microarray Protein List											
Symbol	Protein Name	Location	Symbol	Protein Name	Location						
Brain relevant (52)											
Aβ 42*	Amyloid Beta 42	EC/PM	PNMA1	Paraneoplastic Ma Antigen 1	IC						
ANXA4	Annexin A4	PM	PNMA2	Paraneoplastic Ma Antigen 2	IC						
APP	Amyloid Precursor Protein	EC/PM	S100B	S100 calcium-binding protein	EC						
1004*		D) (C) IC A	B	IC.						
AQP4*	Aquaporin-4	PM	SNCA	alpha-synuclein	IC						
CDH13	Cadnerin 15	EC/PM	55B	(La)	IC.						
CDR2	Cerebellar Degeneration Related Protein 2 (Yo; Purkinje)	IC	Tau*	Tau - 441	EC/PM						
CHRNA10	Cholinergic Receptor Nicotinic Alpha 10 Subunit	PM	TPH1	Tryptophan Hydroxylase 1	IC						
CHRNA9	Cholinergic Receptor Nicotinic Alpha 9 Subunit	PM	TROVE2	TROVE Domain Family Member 2 (Ssa/Ro)	IC						
COL4A3BP	Collagen Type IV Alpha 3 Binding Protein	EC	TUBB3	Tubulin Beta 3	IC						
DCN	Decorin	EC	ZIC4	Zinc finger protein	IC						
DPYSL5	Dihydropyrimidinase-related protein 5 (CRMP5)	IC									
DRD2	Dopamine receptor D2	PM	BBB Relevant	BB Relevant (5)							
ELAVL4	(Embryonic Lethal, Abnormal Vision, Drosophila)-Like 4	IC	BSG	Basigin	РМ						
GABBR1	Gamma-Aminobutyric Acid Type B Receptor Subunit 1	PM	CLDN5	Claudin 5	PM						
GABRA1	Gamma-Aminobutyric Acid Type A Receptor Alpha1 Subunit	PM	LAMC2	Laminin Subunit Gamma 2	PM						
GABRB3	Gamma-Aminobutyric Acid Type A Receptor Beta3 Subunit	PM	TJP1	Tight Junction Protein 1	PM						
GAD1	Glutamate decarboxylase 1 (brain, 67kDa)	PM	SELE	E-Selectin	EC/PM						
GAD2	Glutamate decarboxylase 2 (65, kDa)	PM									
GFAP	Glial Fibrillary Acidic Protein	IC	Non-CNS / Co	ntrol (22)							
GLRA1	Glycine Receptor Alpha 1	PM	ACE	Angiotensin Converting Enzyme	EC/PM						
GRIA2	Glutamate Ionotropic Receptor AMPA Type	PM	BSA	Bovine Serum Albumin	Non-human						
GRIA3	Subunit 2 Glutamate Ionotropic Receptor AMPA Type Subunit 3	РМ	BSA-bio	Bovine Serum Albumin -	Non-human						
GRIA4	Glutamate Ionotropic Receptor AMPA Type Subunit 4	PM	CDH1	Cadherin 1	EC/PM						
GRIN1	Glutamate Ionotropic Receptor NMDA Type Subunit 1	РМ	CEACAM1	Carcinoembryonic Antigen Related Cell Adhesion Molecule 1	EC/PM						
GRIN2A	Glutamate Ionotropic Receptor NMDA Type Subunit 2A	РМ	CEACAM5	Carcinoembryonic Antigen Related Cell Adhesion	EC/PM						
GRIN3A	Glutamate Ionotropic Receptor NMDA Type	PM	CENPB	Centromere protein B	IC						
GRIN3B	Glutamate Ionotropic Receptor NMDA Type	PM	CENPH	Centromere Protein H	IC						
GRINA	Glutamate Ionotropic Receptor NMDA Type	PM	COL1A1	Collagen, type I, alpha 1	EC						
GRM1	Glutamate Metabotropic Receptor 1	PM	COL5A2	Collagen Type V Alpha 2	EC						
GRM2	Glutamate Metabotropic Receptor 2	PM	DBT	Chain Dihydrolipoamide Branched Chain Transceulese F2	IC						
GRM3	Glutamate Metabotropic Receptor 3	PM	DDC	Dopa Decarboxylase	EC						
GRM4	Glutamate Metabotropic Receptor 4	РМ	DLAT	Dihydrolipoamide S- Acetyltransferase	IC						
GRM7	Glutamate Metabotropic Receptor 7	PM	IFNA1	Interferon Alpha 1	EC						
GRM8	Glutamate Metabotropic Receptor 8	PM	KRT18	Keratin 18	EC						
KCNJ10	Potassium Voltage-Gated Channel Subfamily J Member 10 (Kir4 1)	PM	MPO	Myeloperoxidase	EC						
LGI1	Leucine-rich glioma inactivated 1	EC	NUP210	Nucleoporin 210	IC						
MAG	Myelin Associated Glycoprotein	PM	PRTN3	Proteinase 3	EC/PM						
MBP	Myelin Basic Protein	PM	TGM2	Tissue Transglutaminase	EC/PM						
MOG	Myelin Oligodendrocyte Glycoprotein	PM	TPO	Thyroid Peroxidase	EC/PM						
NEFL	Neurofilament Light	IC	TSHR	Thyroid Stimulating Hormone Receptor	PM						
NOVA1	RNA-binding protein Nova-1 (Ri)	IC	ZNF397	Zinc Finger Protein 397	IC						
OMG	Oligodendrocyte Myelin Glycoprotein	PM									

Supplementary Table 1. Full list of antigens printed on custom central nervous system protein microarray. *Location relates to dominant subcellular location of expression derived from UniProtKB database.* * *relates to proteins that were sourced externally from the HuProt library* EC = extracellular, PM = plasma membrane, IC = intracellular

Supplementary Table 2. Statistics for All Group Comparisons											
Discovery		Acute		Subacute							
Polyantigenic IgM	-0.06	[-0.2- 0.13]	1.19	[0.7-1.80]	p<0.0001						
Polyantigenic IgG	-0.34	[-0.47—0.15]	-0.26	[-0.420.09]	p=0.035						
Validation Polyantigenic		Acute		Subacute							
IgM	0.14	[-0.44-0.28]	0.46	[-0.14-1.35]	p<0.001						
Polyantigenic IgG	-0.18	[-0.50-0.26]	0.03	[-0.37-0.50]	p=0.003						
Discovery	Worse	than Expected	As	/ Better than Ex	pected						
Polyantigenic	0.74	[1 00 5 (4]	1.40	[0 41 0 70]	0.01						
IgM	2.74	[1.89-5.64]	1.46	[0.41-2.72]	p=0.01						
Ag Dominant IgM Ag Dominant	1.3	[1-5]	2	[0.3-3]	p=0.43						
IgG	1.5	[0-4.5]	1	[0-6.5]	p=0.70						
Validation	Worse	than Expected	As	/ Better than Ex	vected						
Polyantigenic	0.00	[0 15 1 46]	0.01	[0 2 (1 17]	0.15						
IgM Ag Dominant	0.62	[-0.15-1.46]	0.21	[-0.36-1.1/]	p=0.15						
IgM A.g. Dominant	1	[0-2]	1	[1-2]	p=0.67						
IgG	1	[0-2]	1	[1-2.25]	p=0.33						
Col5a2 IgG	Lung Contusions N			No Lung Contus	ions						
IgG	1.6	[1.14-2.02]	1.11	[1.00-1.17]	p=0.04						
Late	Late		Healthy Controls								
NfL(pg/ml)	31.1	[17.9-61.0]	6.8	[5.6-10.7]	p<0.0001						
GFAP (pg/ml)	73.6	[52.3-123.2]	55	[38.3-79.4]	p=0.05						
		Late		Day 0 Post TPI			Healthy Contr	ols			
Polyantigenic				Duy 01031-11				015			
IgM	0.54	[0.27-0.95]	0.28	[0-0.52]	p=0.0002	-0.27	[-0.56-0.45]	p<0.0001			
Polyantigenic IgG	-0.14	[-0.27—0.01]	-0.33	[-0.450.16]	p<0.0001	-0.44	[-0.530.32]	p<0.0001			
Long-term	Long-term		Healthy Controls								
NfL (pg/ml)	15.8	[8.24-23.8]	14.4	[10.3-17.9]	p=0.4						
GFAP (pg/ml)	145	[110-250]	118	[97-181]	p=0.11						
Polyantigenic				F 0 00 0 01	0.0000						
IgM Polyantigenic	-0.23	[-0.210.31]	-0.31	[-0.380.3]	p=0.0002						
IgG	-0.18	[-0.310.11]	-0.37	[-0.450.28]	p<0.0001						
MAGIøG	-0.35	[-0 69-0 17]	-0.24	[-0 61-0 22]	n=0.85						
SELE IgG	-0.12	[-0.49-0.36]	-0.23	[-0.53-0.46]	p=0.83						
MAG IgM	-0.26	[-0.58-0.25]	-0.24	[-0.53-0.35	p=0.76						

Supplementary Table 2. Values for statistics quoted in body of main text. "Polyantigenic" values refer to the median Z score per patient, "Ag (antigen) dominant" values refers to the number of dominant antibodies against specific antigens detected per patient. MAG/SELE values refer to the Z scores of the particular antigen-specific autoantibody. All values represent Median [IQR].

Supplementary Material